in the p16-positive patients (90.9 vs 70.2%, respectively; p < 0.01). Conclusions The seventh edition of the AJCC/UICC TNM staging system is suitable for use with p16-negative patients; however, it does not effectively discriminate between p16-positive patients. Therefore, the eighth edition of the AJCC/UICC TNM staging system is more suitable for HPV-mediated OPSCC in Japan.
Introduction
Oropharyngeal squamous cell carcinoma (OPSCC) has been traditionally associated with smoking and alcohol consumption [1] . Recently, however, human papillomavirus (HPV) has been recognised as another primary cause of OPSCC [2] . The incidence of OPSCC has been steadily increasing in the USA and Western Europe, while the prevalence of smoking-and alcohol-induced cancers has been declining [3] [4] [5] .
The epidemiologic, clinical and molecular features of HPV-mediated OPSCC are distinct from those of HPVunrelated OPSCC. Patients with HPV-mediated OPSCC are more likely to present with a small primary tumor and more extensive nodal disease [6] . Despite this tendency to present with more advanced nodal disease, patients with HPV-mediated OPSCC have a better prognosis and respond better to treatment than those with HPV-unrelated OPSCC [2, 7] .
Several studies have demonstrated that the seventh edition of the American Joint Committee on Cancer/American Joint Committee on Cancer (AJCC/UICC) TNM staging
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Background Several studies have demonstrated that the seventh edition of the American Joint Committee on Cancer/American Joint Committee on Cancer (AJCC/UICC) TNM staging system does not consistently distinguish between prognostic subgroups for human papillomavirus (HPV)-mediated oropharyngeal squamous cell carcinoma (OPSCC). The eighth edition of the AJCC/UICC TNM staging system came into effect for use with HPV-mediated OPSCC on or after 1 January 2017. This study confirms that the eighth edition of the AJCC/UICC TNM staging system for HPV-mediated OPSCC accurately reflects disease outcomes.
Patients and methods
We retrospectively analyzed 195 patients with OPSCC treated at Hokkaido University Hospital, Sapporo, Japan between 1998 and 2015. HPV status was evaluated by immunohistochemical analysis of p16. Results Of the 195 OPSCC patients evaluated, 111 (56.9%) were p16 positive and 84 (43.1%) were p16 negative. The 3-year overall survival rate (OS) was significantly lower in the p16-negative patients with stage III-IV in comparison with those with stage I-II (55.0 vs. 93.1%, respectively; p < 0.01). The 3-year OS did not differ significantly between stage I-II and stage III-IV in the p16-positive patients (86.7 vs 87.7%). According to the eighth edition of the AJCC/UICC TNM staging system, stage I-II and stage III can be differentiated on the basis of the 3-year OS system does not consistently distinguish between prognostic subgroups for OPSCC as this edition was published before HPV-mediated OPSCC was classified as a disease entity [8, 9] . The International Collaboration on Oropharyngeal cancer Network for Staging (ICON-S) study, which involved the largest dataset from five North American and two European centers, represented an international effort to develop a pretreatment TNM clinical staging classification, with the authors proposing a novel staging system for HPV-mediated OPSCC [10] . The results of this study showed that in terms of outcome the traditional N0 to N2b nodal stages are homogeneous within the T1 and T2 categories (creating Stage I), that N2c and T3 represent an intermediate stage (Stage II) , and T4 and N3 are the least favourable group (Stage III). Stage IV is reserved for distant metastases.
The eighth edition of the AJCC/UICC TNM staging system came into effect for use with HPV-mediated OPSCC on or after 1 January 2017, with HPV-mediated OPSCC treated separately from HPV-unrelated OPSCC. The T (size or direct extent of the primary tumour) categories remain the same as in the seventh edition, with the exception that the HPV-mediated classification does not include a Tis category and there is no T4b within T4 (Table 1 ). There are three N (degree of involvement of regional lymph nodes) categories for HPV-mediated OPSCC: N1, N2 and N3 (Table 2 ). N1 represents one or more ipsilateral lymph node metastases, none larger than 6 cm; N2 represents contralateral or bilateral lymph nodes, none larger than 6 cm; N3 represents lymph node(s) larger than 6 cm. Clinical staging groups are classified as stage I (T1-T2N0-N1), stage II (T1-T2N2 or T3N0-N2), and stage III (T4 or N3) ( Table 3 ). Metastatic disease (M1) is classified as stage IV.
In this study, we evaluated whether the 8th edition of the AJCC/UICC TNM staging system was able to differentiate more effectively between patients with HPV-mediated OPSCC in Japan.

Patients
After institutional research ethics board approval, we retrospectively analysed consecutive patients without distant metastatic OPSCC undergoing definitive treatment at Hokkaido University Hospital, Japan, between 1998 and 2015. All patients were staged according to the AJCC/ UICC TNM staging system (seventh and eighth editions) using findings from physical and endoscopic examinations and from computed tomography (CT), magnetic resonance imaging, and/or fluorodeoxyglucose-positron emission tomography CT imaging. 
Therapy
All patients were managed by a multidisciplinary team, including head and neck surgeons, radiation oncologists and medical oncologists. Patients with early T and N classifications received surgery, radiotherapy or concurrent chemoradiotherapy with a total dose of 65-70 Gy. Those patients with an advanced T or N classification received concurrent chemoradiotherapy using platin-based or docetaxel-based chemotherapy. Therapy for these patients was decided upon without consideration of their p16 status.
p16 Immunohistochemistry
All histological samples were reviewed by expert head and neck pathologists to confirm the diagnosis. Immunohistochemistry (IHC) for p16 was carried out as described previously [11] . The cut-off point for the determination of p16-positivity by IHC was nuclear expression with +2/+3 intensity or greater and ≥75% distribution [12] .
Statistical analysis
Factors associated with p16 status, including gender, age, tumour subsites, alcohol consumption and second primary tumour status, were analysed by cross-tabulations using the two-tailed Fisher's exact test. Statistical significance was set at p < 0.05. Smoking status was analysed by the MannWhitney U test with statistical significance set at p < 0.05. Overall survival (OS) curves were calculated using the Kaplan-Meier method. Survival was calculated from the date of the start of treatment until either death or the last date on which the patient was known to be alive. Probabilities of overall survival, which included death from any cause computed from the beginning of treatment to either death or the last date on which the patient was known to be alive, were calculated by the Kaplan-Meier method and compared using the log-rank test. Statistical significance was set at p < 0.05.
Results
Patient population and p16 IHC
A total of 195 patients with OPSCC were treated with definitive treatment between 1998 and 2015. The demographic and clinicopathological characteristics of these patients are listed in Table 4 Table 7 . Of the 111 patients with p16-positive OPSCC, 67 (60.4%), 25 (22.5%) and 19 (17.1%) were diagnosed as stage I, II and III, respectively. Most of the p16-positive patients were diagnosed as stage I when using the eighth edition of the AJCC/UICC TNM staging system; to the contrary most p16-positive patients were diagnosed as stage IV when using the seventh edition. Figure 2 shows the shift in stage classification from the seventh edition to the eighth edition. All patients diagnosed as stage I and II using the seventh edition were diagnosed as stage I using the eighth edition. Of the 17 patients diagnosed as stage III using the seventh edition, eight were stage I and nine were stage II using the eighth edition. Of the 80 patients diagnosed as stage IV using the seventh edition, 45 patients were diagnosed as stage I and 16 as stage II using the eighth edition. More than half of the patients diagnosed as stage IV using the seventh edition were diagnosed as stage I when the eighth edition was used.
Survival analysis using the eighth edition of the AJCC/ UICC TNM staging system in patients with p16-positive OPSCC
Survival analysis was performed using the eight edition of the AJCC/UICC TNM staging system in patients with p16-positive OPSCC (Fig. 3) . The 3-year overall survival for patients with stage I, II and III was 90.9, 90.9 and 70.2%, respectively. Survival for patients diagnosed as 
Discussion
The results of our study show that using the eighth edition of the AJCC/UICC TNM staging system we were able to effectively discriminate between patients with p16-positive OPSCC in this case series.
In agreement with recently reported findings, we showed that the rate of HPV-mediated OPSCC is increasing in Japan. Maruyama et al. reported that the prevalence of HPV increased from 36.8% during the period from 1995 to 1999 to 39.0% during the period from 2000 to 2009, and to 48.3% between 2010 and 2012 [13] . In a multicenter study carried out in Japan, HPV was detected in 50.3% of cases between 2008 and 2010 [14] . These results suggest that, similar to the trend observed in Western Europe and North America, HPV-mediated OPSCC is increasing in Japan.
The N criteria in HPV-mediated OPSCC have been revised in the eighth edition. Historically, nodal stage has been a dominant prognostic factor in OPSCC [15] . HPVmediated OPSCC has a tendency to metastasise early to lymph nodes regardless of early T-stage, so that most patients with HPV-mediated OPSCC are diagnosed as N2b and then stage IV using the seventh edition. In an era of rising HPV prevalence, the impact of the N stage on prognosis has declined in the population-based cohort [16] . In HPVmediated OPSCC, patients classified as N1-N2b using the seventh edition are classified as N1 using the eighth edition. In the present study, most of the HPV-mediated OPSCC patients were diagnosed as N2b using the seventh edition, but a majority were diagnosed as N1 using the eighth edition. The distribution of clinical stages has shifted due to the revision of N categories. We found that most of the HPV-mediated OPSCC patients were diagnosed as stage IV using the seventh edition but that this shifted to stage I when the eighth edition was used.
Several studies have shown that the seventh edition of the AJCC/UICC TNM staging system was not ideal for risk stratification in patients with HPV-mediated OPSCC [16] [17] [18] [19] . In our study, we did not observe any statistical difference in survival between p16-positive patients with OPSCC at stage I-II and those at stage III-IV using the seventh edition. However, when we used the eighth edition, there was a statistical difference in survival between stage I-II and III patients. These results suggest that the eighth edition is more effective in discriminating among patients with HPVmediated OPSCC in Japan, in the same manner as among Western European and North American patient populations.
There are several limitations related to the use of the eighth edition in HPV-mediated OPSCC. IHC for p16 overexpression is used to classify HPV-mediated OPSCC in the eighth edition. As p16 is upregulated when high-risk HPV oncoproteins degrade p53 and pRB, p16 is a surrogate marker for HPV DNA testing. Direct detection of HPV is not used as a defining factor due to problems associated with its universal availability and applicability, cost and failure to stratify survival, as well as p16 overexpression [12] . However, as a result of other genetic perturbations, patients may overexpress p16 without any relation to HPV. The rate of HPV-negativity among p16-positive patients has been reported to be around 10-20% [2, [20] [21] [22] . The prognosis for p16-positive/HPV-negative OPSCC remains unclear. Lewis et al. reported that patients with p16-positive/HPV-negative OPSCC had significantly better survival than those with p16-negative OPSCC [23] . However, there have been several reports of p16-positive/HPVnegative OPSCC patients having poorer survival than those with p16-positive/HPV-positive OPSCC [24, 25] . Perrone et al. recommend that HPV should be assessed by some method in addition to p16 IHC [24] . Taken together, these reports suggest that we need to remember that there are a small number of patients with p16-positive/HPV-negative OPSCC and that these patients have worse survival than those with p16-negative OPSCC.
The eighth edition of the AJCC/UICC TNM staging system introduces the use of extranodal extension (ENE) in categorizing "N" for neck node metastasis. ENE is one of the most important nodal characteristics influencing prognosis [26] , but it is not categorized in p16-positive OPSCC. Spector et al. reported that matted nodes, defined as three nodes abutting one another with loss of the intervening fat plane that is replaced with evidence of ENE, were a prognostic factor for a poor outcome in HPV-positive OPSCC [27] . Vainshtein et al. also reported that matted nodes were a portent of dramatically increased distant failure and risk of death in HPV-positive OPSCC [28] . These reports suggest that we need to take particular care with p16-positive OPSCC patients with matted nodes. The patients with HPV-mediated OPSCC have favourable clinical outcomes in comparison with HPV-negative patients. However, the treatment for HPV-mediated OPSCC patients is currently the same as that for their HPV-negative counterparts. The current standard of care for OPSCC is derived from older trials of head and neck cancer patients with predominately HPV-negative disease, potentially representing the overtreatment of patients with favorable risk, i.e., those with HPV-mediated OPSCC [29] . A number of clinical trials are now underway to investigate strategies for the de-intensification of treatment in HPVmediated OPSCC patients in order to minimize morbidity while maintaining excellent outcomes. The National Comprehensive Cancer Network guidelines state that the results of HPV testing should not change management decisions except in the context of a clinical trial [30] .
In conclusion, we have demonstrated that the seventh edition of the AJCC/UICC TNM staging system is inadequate for predicting patient survival and that the eighth edition of the AJCC/UICC TNM staging system is able to effectively discriminate among Japanese patients with p16-positive OPSCC.
